Table 1.
Total copies of intestinal bacteria in each group
| Total bacteria (copy number/g) | FC | MO | DI | ZH | GA | KO |
|---|---|---|---|---|---|---|
| 1 | 1,482,131,000 | 14,424,390,000 | 1.30734E+11 | 877,964,800 | 2,532,737 | 821,453,400 |
| 2 | 530,056,400 | 66,255,020,000 | 5.94403E+12 | 1,375,961,000 | 45,190,660 | 84,881,970 |
| 3 | 476,350,900 | 14,133,200,000 | 4.09941E E+12 | 65,151,450 | 69,905,180 | 84,399,230 |
| 4 | 3,238,729,000 | 1.35541E+12 | 41,278,390,000 | 16,213,720 | 144,515,900 | 311,785,000 |
| 5 | 216,104,600 | 2.33782E+11 | 52,287,600,000 | 17,307,860 | 84,531,920 | 178,919,400 |
| 6 | 241,080,800 | 9.06385E+13 | 54,849,440,000 | 10,236,970 | 107,940,800 | 168,030,700 |
| 7 | 4,593,153,000 | 65,143,480,000 | 5.61591E+11 | 3,292,147 | 120,057,200 | 820,202,500 |
| 8 | 11,431,060,000 | 63,403,100,000 | 1.96913E+11 | 5,663,928 | 133,493,100 | 490,321,300 |
FC constipation model group, MO mosapride group was given 2 mg/(kg d) gavage, DI low dose group with 5.15 g/(kg d), ZH medium dose group with 10.3 g/(kg d), GA high dose group with 20.6 g/(kg d) doses, KO control group